|
Advances in FDG PET imaging for staging and prognostic assessment in pediatric lymphoma: a systematic review.
Pediatr Radiol
Ghazi FM, Shafiei S, SeyedAlinaghi S.
PMID: 41348237 [PubMed - as supplied by publisher]
|
|
Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.
Hematology Am Soc Hematol Educ Program
Rojek AE, Smith SM.
PMID: 41348051 [PubMed - indexed for MEDLINE]
|
|
Anticoagulants in hematologic malignancies: what is the data?
Hematology Am Soc Hematol Educ Program
Alyamany R, Houghton DE.
PMID: 41348050 [PubMed - indexed for MEDLINE]
|
|
What to know about rare B-cell malignancies in 2025.
Hematology Am Soc Hematol Educ Program
Fazal S, Samhouri Y, Khan C, Abdulhaq H.
PMID: 41348048 [PubMed - indexed for MEDLINE]
|
|
Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches.
Hematology Am Soc Hematol Educ Program
Raychaudhuri S, Cassaday RD, Percival MM.
PMID: 41348047 [PubMed - indexed for MEDLINE]
|
|
Emerging genomic biomarkers in diagnosis and classification of T-cell acute lymphoblastic leukemia.
Hematology Am Soc Hematol Educ Program
Xu J, Teachey DT.
PMID: 41348046 [PubMed - indexed for MEDLINE]
|
|
Updates in the management of newly diagnosed chronic lymphocytic leukemia.
Hematology Am Soc Hematol Educ Program
McClellan K, Sitlinger A.
PMID: 41348044 [PubMed - indexed for MEDLINE]
|
|
Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML?
Hematology Am Soc Hematol Educ Program
Nicol W, Wei AH.
PMID: 41348039 [PubMed - indexed for MEDLINE]
|
|
The role of MRD monitoring and options for CLL management in relapsed/refractory disease.
Hematology Am Soc Hematol Educ Program
Sworder B, Siddiqi T.
PMID: 41348036 [PubMed - indexed for MEDLINE]
|
|
Molecular subtypes of DLBCL: are we ready to translate our knowledge into the change of treatment paradigms?
Hematology Am Soc Hematol Educ Program
Rutherford SC.
PMID: 41348035 [PubMed - indexed for MEDLINE]
|
|
Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?
Hematology Am Soc Hematol Educ Program
Atluri H, Abaza Y, Altman JK.
PMID: 41348033 [PubMed - indexed for MEDLINE]
|
|
Revisiting novel genomic classifiers in the era of immunotherapy for pediatric B-ALL.
Hematology Am Soc Hematol Educ Program
Wang'ondu RW, Loh ML.
PMID: 41348027 [PubMed - indexed for MEDLINE]
|
|
Could treatment modification based on early response assessment improve results in DLBCL?
Hematology Am Soc Hematol Educ Program
Raman HS, Crombie JL.
PMID: 41348022 [PubMed - indexed for MEDLINE]
|
|
Using genomics to refine pediatric AML risk stratification.
Hematology Am Soc Hematol Educ Program
Pigazzi M, Meshinchi S, Locatelli F.
PMID: 41348020 [PubMed - indexed for MEDLINE]
|
|
Where do immunotherapies stand in management of acute leukemia in adults?
Hematology Am Soc Hematol Educ Program
Boissel N.
PMID: 41348009 [PubMed - indexed for MEDLINE]
|
|
Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T-cell persistence in ALL.
Hematology Am Soc Hematol Educ Program
Gabelli M, Ghorashian S.
PMID: 41348007 [PubMed - indexed for MEDLINE]
|
|
With BiTEs at the kiddie table, where do CARs come in for pediatric B-ALL?
Hematology Am Soc Hematol Educ Program
Li AM, Maude SL.
PMID: 41348006 [PubMed - indexed for MEDLINE]
|
|
Post-HCT maintenance therapy for AML: who, when, why, how long?
Hematology Am Soc Hematol Educ Program
Levis M.
PMID: 41348005 [PubMed - indexed for MEDLINE]
|
|
High-grade B-cell lymphomas: high difficulties to diagnose and treat?
Hematology Am Soc Hematol Educ Program
Davies AJ.
PMID: 41348004 [PubMed - indexed for MEDLINE]
|
|
The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era.
Hematology Am Soc Hematol Educ Program
Gupta S, McNeer J, O'Brien M, Rau R, Teachey D.
PMID: 41347988 [PubMed - indexed for MEDLINE]
|
| |
|
 |
|
